Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Tempest Therapeutics Inc TPST

Healthcare Biotechnology
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:TPST)

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 9 days ago

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

GlobeNewswire 10 days ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

GlobeNewswire October 10, 2024

Tempest Extends Limited Duration Stockholder Rights Plan

GlobeNewswire October 10, 2024

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 20, 2024

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

GlobeNewswire September 18, 2024

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 5, 2024

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 23, 2024

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

GlobeNewswire August 21, 2024
View More News ››

Opinion & Analysis (NDAQ:TPST)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TPST)

Good choice?

Interested in owning stocks. What do you suggest? Tx
Tulsa123 - 12 days ago

Tempest Announces the Appointment of Troy M. Wagner as Vice

News; $TPST Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality AssuranceBRISBANE, Calif., Aug. 21, 2024...
whytestocks - August 21, 2024

Tempest Announces Successful End-of-Phase 2 Meeting with FDA

NEWS: $TPST Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular...
whytestocks - August 15, 2024

Tempest Therapeutics, Inc. (NASDAQ:TPST): A Promising Oncolo

http://beyondspx.com/2024/08/01/tempest-therapeutics-inc-nasdaqtpst-a-promising-oncology-pipeline-backed-by-solid-financials/
MikeTester - August 2, 2024

Tempest Unveils New Survival Data for Amezalpat (TPST-1120)

JUST IN: $TPST Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month...
whytestocks - June 20, 2024

This company is so tight it squeaks , 22 million SO .

Moose Jaw 
Galaxym31 - April 3, 2024
View more Bullboard ››

Fineqia International Inc.

Fineqia International Inc.

Fineqia International Inc. is a digital asset business that builds and targets investments in early and growth stage ...
View More »